Publication details

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Authors	MAHON Francois-Xavier PFIRRMANN Markus DULUCQ Stephanie HOCHHAUS Andreas PANAYIOTIDIS Panayiotis ALMEIDA Antonio MAYER Jiří HJORTH-HANSEN Henrik JANSSEN Jeroen J W M MUSTJOKI Satu MARTINEZ-LOPEZ Joaquin VESTERGAARD Hanne EHRENCRONA Hans POLAKOVA Katerina Machova OLSSON-STROEMBERG Ulla OSSENKOPPELE Gert BERGER Marc G ETIENNE Gabriel DENGLER Jolanta BRUEMMENDORF Tim H BURCHERT Andreas REA Delphine ROUSSELOT Philippe NICOLINI Franck E HOFMANN Wolf-Karsten RICHTER Johan SAUSSELE Susanne
Year of publication	2024
Type	Article in Periodical
Magazine / Source	Journal of clinical oncology
MU Faculty or unit	Faculty of Medicine
Citation
web	https://ascopubs.org/doi/10.1200/JCO.23.01647
Doi	http://dx.doi.org/10.1200/JCO.23.01647
Keywords	Chronic Myeloid Leukemia; EURO-SKI
Description	Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.